Kenneth Cusi
University of Florida · North Florida/South Georgia Veterans Health System, Gainesville, FL · University of Flordia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kenneth Cusi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04501406 · Low-Dose Pioglitazone in Patients With NASH (AIM 2)University of Florida · recruiting · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis · principal investigator
- Ph2NCT03459079 · Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseUniversity of Florida · completed · Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) · principal investigator
- Ph4NCT01006889 · Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver DiseaseUniversity of Florida · completed · Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus · principal investigator
- Ph4NCT01002547 · Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of TreatmentVA Office of Research and Development · completed · Nonalcoholic Steatohepatitis · principal investigator
- Ph4NCT00998335 · Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 DiabetesUniversity of Florida · completed · Type 2 Diabetes · principal investigator
- Ph4NCT00994682 · University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)University of Florida · completed · Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus · principal investigator
- Ph4NCT00227110 · Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)The University of Texas Health Science Center at San Antonio · completed · Nonalcoholic Steatohepatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERSU01DK108320 · NIDDK · UNIVERSITY OF FLORIDA · fiscal years 2015 to 2024 · $437,436 awarded in 2024Same name and institution; not confirmed by an ID
- Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASHR01DK120331 · NIDDK · UNIVERSITY OF FLORIDA · fiscal years 2020 to 2023 · $538,644 awarded in 2023Grant number is on one of their registry trials
- NAFLD in T2DM: Prevalence in Hispanics and Role of TreatmentI01CX000167 · VA · VETERANS HEALTH ADMINISTRATION · fiscal years 2009 to 2014Same name and institution; not confirmed by an ID
- BETA-CELL LIPOTOXICITY IN MAS: PROT 1: EFFECT OF GLUCOSE TOXICITY ON B-CELL FUNCM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2004 to 2008 · $174 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:19 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.N Engl J Med · 20211,668 citationsRCR 109.3
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med · 20061,441 citationsRCR 34.1
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.Ann Intern Med · 2016829 citationsRCR 29.9
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol · 2022435 citationsRCR 36.2
- 384 citationsRCR 8.2
- Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab · 1996375 citationsRCR 9.5
- Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.Hepatology · 2021324 citationsRCR 20.3
- Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.Diabetes Care · 2001322 citationsRCR 7.7
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.Diabetes Care · 2019248 citationsRCR 11.6
- 247 citationsRCR 5.9